Daprodustat APIs form a part of Loncom Pharma's commitment to advancing treatment for anemia associated with chronic kidney disease. These APIs function as HIF prolyl-hydroxylase inhibitors, stimulating erythropoiesis and reducing the need for traditional erythropoietin-stimulating agents.
